Five new cases of syndromic intellectual disability due to KAT6A mutations: widening the molecular and clinical spectrum.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
10 02 2020
Historique:
received: 18 10 2019
accepted: 28 01 2020
entrez: 12 2 2020
pubmed: 12 2 2020
medline: 22 6 2021
Statut: epublish

Résumé

Pathogenic variants of the lysine acetyltransferase 6A or KAT6A gene are associated with a newly identified neurodevelopmental disorder characterized mainly by intellectual disability of variable severity and speech delay, hypotonia, and heart and eye malformations. Although loss of function (LoF) mutations were initially reported as causing this disorder, missense mutations, to date always involving serine residues, have recently been associated with a form of the disorder without cardiac involvement. In this study we present five new patients, four with truncating mutations and one with a missense change and the only one not presenting with cardiac anomalies. The missense change [p.(Gly359Ser)], also predicted to affect splicing by in silico tools, was functionally tested in the patient's lymphocyte RNA revealing a splicing effect for this allele that would lead to a frameshift and premature truncation. An extensive revision of the clinical features of these five patients revealed high concordance with the 80 cases previously reported, including developmental delay with speech delay, feeding difficulties, hypotonia, a high bulbous nose, and recurrent infections. Other features present in some of these five patients, such as cryptorchidism in males, syndactyly, and trigonocephaly, expand the clinical spectrum of this syndrome.

Sections du résumé

BACKGROUND
Pathogenic variants of the lysine acetyltransferase 6A or KAT6A gene are associated with a newly identified neurodevelopmental disorder characterized mainly by intellectual disability of variable severity and speech delay, hypotonia, and heart and eye malformations. Although loss of function (LoF) mutations were initially reported as causing this disorder, missense mutations, to date always involving serine residues, have recently been associated with a form of the disorder without cardiac involvement.
RESULTS
In this study we present five new patients, four with truncating mutations and one with a missense change and the only one not presenting with cardiac anomalies. The missense change [p.(Gly359Ser)], also predicted to affect splicing by in silico tools, was functionally tested in the patient's lymphocyte RNA revealing a splicing effect for this allele that would lead to a frameshift and premature truncation.
CONCLUSIONS
An extensive revision of the clinical features of these five patients revealed high concordance with the 80 cases previously reported, including developmental delay with speech delay, feeding difficulties, hypotonia, a high bulbous nose, and recurrent infections. Other features present in some of these five patients, such as cryptorchidism in males, syndactyly, and trigonocephaly, expand the clinical spectrum of this syndrome.

Identifiants

pubmed: 32041641
doi: 10.1186/s13023-020-1317-9
pii: 10.1186/s13023-020-1317-9
pmc: PMC7011274
doi:

Substances chimiques

Histone Acetyltransferases EC 2.3.1.48
KAT6A protein, human EC 2.3.1.48

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

44

Références

Am J Hum Genet. 2009 Apr;84(4):524-33
pubmed: 19344873
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):9585-90
pubmed: 24979783
Hum Mutat. 2013 Aug;34(8):1057-65
pubmed: 23636887
Sci Rep. 2017 Mar 10;7:44138
pubmed: 28281571
Nat Genet. 2014 Sep;46(9):944-50
pubmed: 25086666
J Pediatr Genet. 2017 Jun;6(2):77-83
pubmed: 28496994
J Hum Genet. 2018 Sep;63(9):997-1001
pubmed: 29899504
Am J Med Genet A. 2017 Jan;173(1):62-71
pubmed: 27615324
Nucleic Acids Res. 2017 Jan 4;45(D1):D865-D876
pubmed: 27899602
Clin Transl Allergy. 2017 Jun 22;7:19
pubmed: 28649320
Nucleic Acids Res. 2018 Jul 2;46(W1):W545-W553
pubmed: 29860484
J Pediatr Genet. 2019 Mar;8(1):10-14
pubmed: 30775047
J Gen Intern Med. 2014 Aug;29 Suppl 3:S780-7
pubmed: 25029978
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3895-900
pubmed: 23431171
J Pediatr Genet. 2018 Sep;7(3):114-116
pubmed: 30105118
Eur J Hum Genet. 2018 Jun;26(6):778-785
pubmed: 29487416
Genes Chromosomes Cancer. 2004 Jun;40(2):140-5
pubmed: 15101047
Oncogene. 2002 Apr 18;21(17):2729-40
pubmed: 11965546
Am J Med Genet A. 2017 Sep;173(9):2562-2565
pubmed: 28636259
Clin Cancer Res. 2015 Oct 15;21(20):4709-18
pubmed: 26071483
Hum Genome Var. 2017;4:17045
pubmed: 31754438
Int J Environ Res Public Health. 2018 Aug 14;15(8):
pubmed: 30110963
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Am J Hum Genet. 2015 Mar 5;96(3):507-13
pubmed: 25728777
Am J Hum Genet. 2015 Mar 5;96(3):498-506
pubmed: 25728775
Genet Med. 2019 Apr;21(4):850-860
pubmed: 30245513
Am J Med Genet A. 2016 Jul;170(7):1791-8
pubmed: 27133397
Genes Dev. 2006 May 15;20(10):1321-30
pubmed: 16702405

Auteurs

Roser Urreizti (R)

Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, IBUB, IRSJD, Barcelona, Spain. roseruf@yahoo.es.
Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. roseruf@yahoo.es.
Present address: Neurometabolic Unit, Hospital Sant Joan de Déu, Barcelona, Spain. roseruf@yahoo.es.

Estrella Lopez-Martin (E)

Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Antonio Martinez-Monseny (A)

Department of Genetic and Molecular Medicine and Pediatric Rare Diseases Institute (IPER), Institut de Recerca Sant Joan de Déu (IRSJD), Hospital Sant Joan de Déu, Barcelona, Spain.

Montse Pujadas (M)

Genetics Unit, University Pompeu Fabra, Hospital del Mar Research Institute IMIM, Barcelona, Spain.

Laura Castilla-Vallmanya (L)

Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, IBUB, IRSJD, Barcelona, Spain.
Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Luis Alberto Pérez-Jurado (LA)

Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Genetics Unit, University Pompeu Fabra, Hospital del Mar Research Institute IMIM, Barcelona, Spain.
Women's and Children's Hospital, South Australian Health and Medical Research Institute and The University of Adelaide, Adelaide, Australia.

Mercedes Serrano (M)

Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Department of Neurology, Hospital Sant Joan de Déu, Barcelona, Spain.

Daniel Natera-de Benito (D)

Department of Neurology, Hospital Sant Joan de Déu, Barcelona, Spain.

Beatriz Martínez-Delgado (B)

Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Manuel Posada-de-la-Paz (M)

Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Javier Alonso (J)

Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Purificación Marin-Reina (P)

Dysmorpholgy and Clinical Genetics, Division of Neonatology, Neonatal Research Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Mar O'Callaghan (M)

Department of Neurology, Hospital Sant Joan de Déu, Barcelona, Spain.

Daniel Grinberg (D)

Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, IBUB, IRSJD, Barcelona, Spain.
Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Eva Bermejo-Sánchez (E)

Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Susanna Balcells (S)

Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, IBUB, IRSJD, Barcelona, Spain.
Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH